8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each...
The post Form 8.3 - Warehouse REIT Plc appeared first on Crypto Insider.
]]>8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
| (a) Full name of discloser: | Rathbones Group Plc |
| (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. |
|
| (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree |
Warehouse REIT Plc |
| (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: | |
| (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure |
12/03/2025 |
| (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” |
No |
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
| Class of relevant security: | 1p Ordinary Shares | |||
| Interests | Short positions | |||
| Number | % | Number | % | |
| (1) Relevant securities owned and/or controlled: | 68,535,562 | 16.13% | ||
| (2) Cash-settled derivatives: | ||||
| (3) Stock-settled derivatives (including options) and agreements to purchase/sell: | ||||
|
TOTAL: |
68,535,562 | 16.13% | ||
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors’ and other employee options)
| Class of relevant security in relation to which subscription right exists: | |
| Details, including nature of the rights concerned and relevant percentages: |
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
| Class of relevant security | Purchase/sale | Number of securities | Price per unit |
| 1p Ordinary Shares | Sale | 250,000 | 104.4p |
| 1p Ordinary Shares | Sale | 10,000 | 103.7237p |
| 1p Ordinary Shares | Sale | 71,680 | 103.2p |
| 1p Ordinary Shares | Sale | 4,710 | 103.4657p |
| 1p Ordinary Shares | Sale | 2,600 | 103.4665p |
| 1p Ordinary Shares | Sale | 1,000 | 103.4673p |
| 1p Ordinary Shares | Sale | 2,430 | 103.44p |
| 1p Ordinary Shares | Sale | 5,300 | 104.2441p |
| 1p Ordinary Shares | Sale | 115,000 | 104.5p |
| 1p Ordinary Shares | Sale | 2,149 | 101.76p |
(b) Cash-settled derivative transactions
| Class of relevant security | Product description e.g. CFD |
Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position |
Number of reference securities | Price per unit |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
| Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates | Exercise price per unit | Type e.g. American, European etc. |
Expiry date | Option money paid/ received per unit |
(ii) Exercise
| Class of relevant security | Product description e.g. call option |
Exercising/ exercised against | Number of securities | Exercise price per unit |
(d) Other dealings (including subscribing for new securities)
| Class of relevant security | Nature of dealing e.g. subscription, conversion |
Details | Price per unit (if applicable) |
| 1p Ordinary Shares | Internal transfer from Execution-Only to Discretionary account | 94,825 |
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
| Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” |
| None |
(b) Agreements, arrangements or understandings relating to options or derivatives
| Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” |
| None |
(c) Attachments
| Is a Supplemental Form 8 (Open Positions) attached? | No |
| Date of disclosure: | 13/03/2025 |
| Contact name: | Chinwe Enyi – Compliance Department |
| Telephone number: | 0151 243 7053 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at.
The post Form 8.3 - Warehouse REIT Plc appeared first on Crypto Insider.
]]>8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each...
The post Form 8.3 - Renewi Plc appeared first on Crypto Insider.
]]>8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
| (a) Full name of discloser: | Rathbones Group Plc |
| (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. |
|
| (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree |
Renewi Plc |
| (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: | |
| (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure |
12/03/2025 |
| (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” |
No |
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
| Class of relevant security: | £1 Ordinary Shares | |||
| Interests | Short positions | |||
| Number | % | Number | % | |
| (1) Relevant securities owned and/or controlled: | 1,328,986 | 1.64% | ||
| (2) Cash-settled derivatives: | ||||
| (3) Stock-settled derivatives (including options) and agreements to purchase/sell: | ||||
|
TOTAL: |
1,328,986 | 1.64% | ||
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors’ and other employee options)
| Class of relevant security in relation to which subscription right exists: | |
| Details, including nature of the rights concerned and relevant percentages: |
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
| Class of relevant security | Purchase/sale | Number of securities | Price per unit |
| £1 Ordinary Shares | Sale | 650 | 852.3p |
| £1 Ordinary Shares | Sale | 670 | 853.05p |
| £1 Ordinary Shares | Sale | 4,730 | 853.05p |
(b) Cash-settled derivative transactions
| Class of relevant security | Product description e.g. CFD |
Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position |
Number of reference securities | Price per unit |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
| Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates | Exercise price per unit | Type e.g. American, European etc. |
Expiry date | Option money paid/ received per unit |
(ii) Exercise
| Class of relevant security | Product description e.g. call option |
Exercising/ exercised against | Number of securities | Exercise price per unit |
(d) Other dealings (including subscribing for new securities)
| Class of relevant security | Nature of dealing e.g. subscription, conversion |
Details | Price per unit (if applicable) |
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
| Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” |
| None |
(b) Agreements, arrangements or understandings relating to options or derivatives
| Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” |
| None |
(c) Attachments
| Is a Supplemental Form 8 (Open Positions) attached? | No |
| Date of disclosure: | 13/03/2025 |
| Contact name: | Chinwe Enyi – Compliance Department |
| Telephone number: | 0151 243 7053 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at.
The post Form 8.3 - Renewi Plc appeared first on Crypto Insider.
]]>Tustin, Ca, March 12, 2025 (GLOBE NEWSWIRE) -- Canon Medical Systems USA is proud to announce the U.S. market launch of the Adora DRFi, following its FDA 510(k) clearance on December 23, 2024. The Adora DRFi, a cutting-edge hybrid imaging system, is now available for quoting and sale, delivering a transformative approach to radiographic and fluoroscopic imaging in a single solution. The Adora DRFi seamlessly combines static and dynamic radiography with low-dose fluoroscopy, enhancing workflow efficiency and equipment utilization for...
The post Canon Medical Systems USA Announces FDA Clearance and Market Availability of Adora DRFi: An Automated Hybrid Solution for Radiography and Fluoroscopy appeared first on Crypto Insider.
]]>Tustin, Ca, March 12, 2025 (GLOBE NEWSWIRE) — Canon Medical Systems USA is proud to announce the U.S. market launch of the Adora DRFi, following its FDA 510(k) clearance on December 23, 2024. The Adora DRFi, a cutting-edge hybrid imaging system, is now available for quoting and sale, delivering a transformative approach to radiographic and fluoroscopic imaging in a single solution.
The Adora DRFi seamlessly combines static and dynamic radiography with low-dose fluoroscopy, enhancing workflow efficiency and equipment utilization for healthcare providers. Each functional aspect of the system is designed with end users in mind, featuring a rotating ceiling unit with independently moving X-ray tube and detector arms that enable exposures from virtually any angle. With innovative PositionAnywhere technology, the Adora DRFi moves to accommodate the patient rather than requiring the patient to adjust. The system incorporates the new CXDI-RF Wireless B1 Detector, which can be docked for fluoroscopy and DR exams or used wirelessly for seamless imaging throughout the exam room. Its durable carbon fiber patient table offers a high load capacity, a floating tabletop, and up to 340° rotation, ensuring easy access and flexibility for patients and clinicians. Fully automated movements, coupled with intuitive workflow options like the inMotion auto-positioning technology, enable fast and intelligent operation helping to reduce physical strain on staff.
“Adora DRFi is a testament to Canon Medical’s dedication to delivering innovative solutions that prioritize both clinical excellence and patient care,” said Satrajit Misra, Chief Sales and Marketing Officer of Canon Medical Systems USA. “This system combines versatility, efficiency, and advanced imaging technology in a way that redefines what’s possible in a hybrid radiography and fluoroscopy system. We are excited to bring this innovative product to the U.S. market and help healthcare providers meet the growing demands of modern radiology.”
Designed to address the diverse needs of today’s radiology departments, the Adora DRFi empowers healthcare providers to perform radiographic and fluoroscopic exams in a single room, optimizing space, helping to reduce patient movement, and improving overall workflow efficiency. The design of the ceiling unit enables horizontal projections and complex procedures, such as axial hip imaging, without the need to reposition the patient. The system also includes optional features like an integrated patient hoist, inControl console, and remote operation capabilities, all tailored to streamline processes and enhance the patient and clinician experience.
“The Adora DRFi is a game-changer for radiology departments, offering unmatched versatility and precision,” said Charles Cassudakis, Managing Director of the X-ray Business Unit. “Every detail of this system was developed with the user in mind, from the ergonomic design to the cutting-edge imaging capabilities. This is more than just an imaging system: it’s a tool that will transform how healthcare providers approach radiography and fluoroscopy, enabling better care and patient outcomes.”
The Adora DRFi underscores Canon Medical Systems USA’s ongoing commitment to advancing diagnostic imaging through innovation, intuitive design, and a customer-first approach. For more information or to schedule a demonstration click here.
About Canon Medical Systems USA, Inc.
Canon Medical Systems USA, Inc., headquartered in Tustin, Calif., markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, molecular imaging, ultrasound, X-ray, and interventional X-ray equipment. For more information, visit Canon Medical Systems’ website: https://us.medical.canon/
About Canon Medical Systems Corporation
Canon Medical offers a full range of diagnostic medical imaging solutions, including CT, X-Ray, Ultrasound, Vascular and MR, as well as a full suite of Healthcare IT solutions across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort, and safety features. At Canon Medical, we work hand-in-hand with our partners – our medical, academic and research communities. We build relationships based on transparency, trust, and respect. Together, we strive to create industry-leading solutions that deliver an enriched quality of life. For more information, visit the Canon Medical website: https://global.medical.canon/
The post Canon Medical Systems USA Announces FDA Clearance and Market Availability of Adora DRFi: An Automated Hybrid Solution for Radiography and Fluoroscopy appeared first on Crypto Insider.
]]>Informa Connect Medical Division announces landmark Geneva-based conference, convening the world's foremost industry leaders to forge strategic partnerships, accelerate breakthroughs, and fuse science, capital, and innovation.GENEVA, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- As extending healthy human lifespan evolves beyond theoretical possibility, Informa Connect pushes boundaries with the launch of its Global Longevity Summit. This high-impact event will debut October 28-30, 2025, at the state-of-the-art Genolier Innovation Hub in Geneva, Switzerland. Convening a selected delegation of 300 innovators from 15+...
The post Inaugural Global Longevity Summit Architects New Horizons In Human Health Potential appeared first on Crypto Insider.
]]>GENEVA, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) — As extending healthy human lifespan evolves beyond theoretical possibility, Informa Connect pushes boundaries with the launch of its Global Longevity Summit. This high-impact event will debut October 28-30, 2025, at the state-of-the-art Genolier Innovation Hub in Geneva, Switzerland.
Convening a selected delegation of 300 innovators from 15+ nations, the Summit aims to accelerate global advancements in human health and longevity. By dismantling conventional silos that have long fragmented longevity research, the gathering ensures that breakthrough discoveries merge with real-world implementation expertise and strategic investment.
The Summit unfolds a three-day intensive immersion under the theme “Mastering the Aging Clock: The Science of Longevity.” Through dynamic, interactive sessions, the curated program will explore pivotal domains – epigenetics, regenerative medicine, AI-powered health optimization, and precision interventions – each analyzed through a pragmatic lens of global impact and immediate scalability.
A distinguished Scientific Advisory Board will guide this event, featuring renowned pioneers committed to advancing the science of aging and health optimization:
- James Ho, MD, PhD, DABCC | China | Specialist in molecular diagnostics and therapeutic development, president of RND Health.
- Gordan Lauc, PhD | Croatia | Leading authority on glycobiology and aging biomarkers, director of the National Centre of Scientific Excellence in Personalized Healthcare, CEO and founder of Genos, and CSO of GlycanAge.
- Andrea B. Maier, MD, PhD, FRACP | Singapore | Expert in geriatric medicine and aging research, co-director of the Center for Healthy Longevity.
- Erik Nelson | United States | Innovator in longevity telemedicine and regenerative therapies, co-founder and clinical director of Human Sync.
- Jennifer Pearlman, MD, CCFP, FAARM, ABAARM | Canada | Expert in precision medicine and aging interventions, CEO and founder of PearlMD Rejuvenation.
The Summit’s exclusive location leverages Switzerland’s established leadership in precision medicine, biotechnology research, and healthcare ingenuity. Designed to stimulate interdisciplinary collaboration and connection, the Genolier Innovation Hub situates participants at the intersection of international scientific progress and potential, offering unprecedented opportunities to forge the path forward.
The Global Longevity Summit is an invitation-only event requiring participant application and approval. Qualified leaders in the longevity ecosystem are invited to apply for a limited number of delegate positions. Early submission is encouraged.
For more information, including delegate applications and partnership opportunities, visit https://bit.ly/GlobalLongevitySummit2025.
About The Global Longevity Summit
The Global Longevity Summit is the definitive gathering of international leaders dedicated to advancing human longevity through scientific innovation and strategic collaboration. The invitation-only conference unites distinguished researchers, investors, entrepreneurs, and industry stakeholders to accelerate breakthroughs in life extension and power the future of longevity science and business.
Contact:
Drew Wilson
drew.wilson@informa.com
(+1) 713-725-8983
The post Inaugural Global Longevity Summit Architects New Horizons In Human Health Potential appeared first on Crypto Insider.
]]>SEOUL, South Korea, March 11, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, announced today that Chief Financial Officer, Joe Sigrist, will participate in two upcoming institutional investor conferences: 37th Annual Roth Conference Location: The Laguna Cliffs Marriot Resort & Spa - Dana Point, CADate: Tuesday, March 18, 2025Format: One-on-one meetings with institutional investors iAccess Alpha Virtual Best Ideas Spring Investment Conference Location:...
The post DoubleDown Interactive to Participate in Upcoming Investor Conferences appeared first on Crypto Insider.
]]>SEOUL, South Korea, March 11, 2025 (GLOBE NEWSWIRE) — DoubleDown Interactive (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, announced today that Chief Financial Officer, Joe Sigrist, will participate in two upcoming institutional investor conferences:
37th Annual Roth Conference
- Location: The Laguna Cliffs Marriot Resort & Spa – Dana Point, CA
- Date: Tuesday, March 18, 2025
- Format: One-on-one meetings with institutional investors
iAccess Alpha Virtual Best Ideas Spring Investment Conference
- Location: Virtual
- Date: Tuesday, March 25, 2025 and Wednesday, March 26, 2025
- Format:
- To register and schedule a one-on-one meeting with DoubleDown, please visit the conference website https://www.iaccessalpha.com/home.
If you have questions about DoubleDown or are interested in conducting a conference call or meeting with management, please contact the company’s investor relations firm, JCIR, at (212) 835-8500 or via email at ddi@jcir.com.
About DoubleDown Interactive
DoubleDown Interactive Co., Ltd. is a leading developer and publisher of digital games on mobile and web-based platforms. We are the creators of multi-format interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. The Company’s flagship social casino title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games. The Company’s subsidiary, SuprNation, also operates three real-money iGaming sites in Western Europe.
Company Contact:
Joe Sigrist
ir@doubledown.com
+1 (206) 773-2266
Chief Financial Officer
https://www.doubledowninteractive.com
Investor Relations Contact:
Joseph Jaffoni or Richard Land
JCIR
+1 (212) 835-8500
DDI@jcir.com
The post DoubleDown Interactive to Participate in Upcoming Investor Conferences appeared first on Crypto Insider.
]]>Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: Robotics: Optimizing and personalizing surgery With CORIOGRAPH◊ Pre-Op Planning and Modeling Services advanced technology and the CORI Surgical System's image-agnostic solution for robotic-assisted knee and computer-guided hip replacement procedures, Smith+Nephew offers a highly personalized approach for both surgeons and their...
The post Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025 appeared first on Crypto Insider.
]]>Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:
Robotics: Optimizing and personalizing surgery
With CORIOGRAPH◊ Pre-Op Planning and Modeling Services advanced technology and the CORI Surgical System’s image-agnostic solution for robotic-assisted knee and computer-guided hip replacement procedures, Smith+Nephew offers a highly personalized approach for both surgeons and their patients. CORIOGRAPH’s recent addition of support for hip procedures expands the platform’s reach to provide advanced planning and simulation technology for THA. A defining feature of the technology is the ability to simulate a patient’s functional activities of daily living (ADLs) specific to their anatomy.1
Alongside these advancements, the CORI◊ Digital Tensioner enhances the level of personalization in knee procedures by providing objective gap data for planning and execution of the procedure.2-4 Now available for UKA, TKA, and Revision TKA, the CORI Digital Tensioner is designed to deliver accurate gap balance measurements with the CORI Surgical System for optimizing the surgical plan to align with each patient’s unique soft tissue anatomy.
These cutting-edge technologies enable a highly personalized and tailored surgical approach with the CORI Surgical System, ensuring that patient-specific needs are met. Learn more by visiting the CORIOGRAPH webpage here.
Hips: Best-in-class just got better
Smith+Nephew’s new CATALYSTEM◊ Primary Hip System is designed to address the evolving demands of primary hip surgery – including the increased adoption of anterior approach procedures. It features a triple-taper stem design with uniform proximal loading,5 and the reduced distal stem geometry and shorter lengths are ideal for anterior approach – and suitable for all approaches.6
Smith+Nephew’s total hip arthroplasty (THA) portfolio was recently recognized in the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry. It highlighted the exceptional performance of proprietary OXINIUM◊ (Oxidized Zirconium) on highly cross-linked polyethylene where the data indicated the combination has the highest survivorship rate (>94.1%) among all bearing combinations over a 20-year period for THA.7 Read the press release here.
Knees: Raising the bar in revisions
Smith+Nephew recently launched proprietary OXINIUM implant technology on the LEGION◊ Hinged Knee (HK) System that delivers the durability of metals, the wear resistance of ceramics, and corrosion resistance better than both metal and ceramic.8-14 Part of the LEGION Total Knee (TK) System, the LEGION HK System is designed to provide a natural range of motion with medial pivot, lateral roll back, and screw home. Since 2011, the LEGION HK System has enabled surgeons to transition intraoperatively from a constrained revision knee implant to a CoCr-hinged assembly. Learn more by visiting the LEGION HK webpage here.
AETOS◊ Shoulder System: Elegant design. Elevated experience.
Smith+Nephew recently received 510(k) clearance from the FDA for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless). AETOS Stemless addresses the growing demand for anatomic total shoulder replacement with a small operating room footprint allowing for an efficient procedure.15 It is designed to maximize metaphyseal fixation and stability with an inlay collar, cruciate fins, and porous titanium coating to encourage biological fixation.16,17 Learn more by visiting the AETOS webpage here.
To learn more about Smith+Nephew’s advanced solutions for Orthopaedic Reconstruction, please visit our booth (#3729) at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in San Diego March 11-13, 2025 or visit wwww.smith-nephew.com.
– ends –
Media Enquiries
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
References
- Smith+Nephew 2020. Internal Report. EA/RECON/VISIONAIRE/001/v6.
- Smith+Nephew 2022. Optimus TKA Tensioner Gap Assessment Verification Report. Internal Report. 10059269.
- Smith+Nephew 2022. Tensioner KPC: Tensioner Calibration Check. Internal Report. TR100116, REV B.
- Smith+Nephew 2022. CORI TENSIONER. 2020.04 Study Cases. Preliminary Analysis Report REV B.
- Smith + Nephew 2024. Finite Element Analysis of the CATALYSTEM Hip Stem Design. Internal Report. OR-24-025
- Smith + Nephew 2024. Surgeon Feedback on the CATALYSTEM Total Hip System. Internal Report. CSD.REC.24.001
- Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2024 Annual Report Adelaide; AOA, 2024:1–629. Available at: https://aoanjrr.sahmri.com/annual-reports-2024. Accessed December 11, 2024.
- Sheth NP, Lementowski P, Hunter G, Garino JP. Clinical applications of oxidized zirconium. J Surg Orthop Adv. 2008;17(1):17-26.
- Davidson JA, Mishra AK, Poggie RA. Friction and UHMWPE wear of cobalt alloy, zirconia, titanium nitride, and amorphous diamond-like carbon implant bearing surfaces. Poster presented at: 4th World Biomaterials Con1992; Berlin, FRG.
- Hobbs L, Rozen V, Mangin S, Treska M. Oxidation Microstructures and Interfaces in the Oxidized Zirconium Knee. Int J Appl Ceram Technol. 2005.
- Long M, Riester L, Hunter G. Nano-Hardness Measurements of Oxidized Zr.2.5Nb and Various Orthopaedic Materials. 1998.
- Smith+Nephew 2010. Hip Simulator Wear Testing of XLPE Liners Against Oxidized Zr-2.5Nb and BIOLOX Delta Heads. Interal Report. OR-10-155
- Smith+Nephew 2010. OR-10-155.
- Smith+Nephew 2016. OR-16-127
- Smith+Nephew 2023. AETOS Instruments & Trays.
- Internal Report. ER-04-0990-0020 REV B
- Pilliar RM. Cementless implant fixation—toward improved reliability. Orthopedic Clinics of North America. 2005;36(1):113-119
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
.
The post Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025 appeared first on Crypto Insider.
]]>CHICAGO, March 10, 2025 (GLOBE NEWSWIRE) -- Oil-Dri Corporation of America (NYSE: ODC), a leader in lightweight cat litter, will be exhibiting at the 2025 Global Pet Expo, taking place March 26-28 at the Orange County Convention Center in Orlando, Florida. Attendees are invited to visit Oil-Dri at Booth 2020 to explore their innovative brands, including Cat’s Pride®, Jonny Cat®, and Ultra® as well as private label opportunities. As pioneers in lightweight litter innovation, Oil-Dri is dedicated to delivering high-performing...
The post Oil-Dri Corporation of America to Showcase Innovative Lightweight Cat Litter Products at 2025 Global Pet Expo appeared first on Crypto Insider.
]]>CHICAGO, March 10, 2025 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), a leader in lightweight cat litter, will be exhibiting at the 2025 Global Pet Expo, taking place March 26-28 at the Orange County Convention Center in Orlando, Florida. Attendees are invited to visit Oil-Dri at Booth 2020 to explore their innovative brands, including Cat’s Pride®, Jonny Cat®, and Ultra® as well as private label opportunities.
As pioneers in lightweight litter innovation, Oil-Dri is dedicated to delivering high-performing lightweight products that meet the needs of both retailers and consumers. Under the leadership of third-generation President and Chief Executive Officer, Daniel S. Jaffee, Oil-Dri continues to break boundaries in product development, consistently focusing on improving the lives of cats and their owners.
After acquiring crystal cat litter supplier Ultra Pet Company, Inc. in 2024, Oil-Dri now offers Cat’s Pride Micro Crystal Litter which instantly absorbs moisture and controls odors for up to 30 days, providing consumers with the ultimate in convenience. Additionally, Oil-Dri’s latest innovations include Cat’s Pride Antibacterial Clumping Litter – the first and only EPA-approved antibacterial litter in the U.S. that kills 99.9% of odor-causing bacteria for a cleaner, more sanitary litter box. Jonny Cat continues to offer high-performance, cost-effective non-clumping litters and litter box liners for everyday use.
“We’re incredibly excited to bring these groundbreaking products to the Global Pet Expo,” says Laura Scheland, Vice President & General Manager of Consumer Products Division at Oil-Dri Corporation. “We are able to serve retailers and consumers with both branded and private label options in lightweight clumping, non-clumping, clay, and crystal formulas as well as accessories. Whatever your preference, we have the right solution.”
Oil-Dri remains committed to sustainability and environmental responsibility in producing innovative, quality products that will benefit both cat owners and the environment. Our lightweight cat litter products are lighter than traditional heavy scoopable clay litters, enabling us to load nearly twice as many lightweight units on a truck, reducing the number of trucks on the road. This efficiency helps reduce the carbon footprint associated with transportation, furthering our dedication to a healthier planet.
Oil-Dri’s booth at the 2025 Global Pet Expo will showcase the full range of Cat’s Pride, Jonny Cat, and Ultra products. Whether you are a retailer or a consumer, Oil-Dri has everything you need to make your cat’s litter experience better. Stop by Booth 2020 to chat with our team, learn about our latest innovations, and discover how we can help you meet the needs of your customers.
For more information about Oil-Dri’s cat litter products, please visit catspride.com.
About Oil-Dri Corporation of America
Oil-Dri Corporation of America, the maker of Cat’s Pride litter, is a leading manufacturer and supplier of specialty sorbent products for the pet care, animal health and nutrition, fluids purification, agricultural ingredients, sports field, industrial and automotive markets. Oil-Dri is vertically integrated which enables the Company to efficiently oversee every step of the process from research and development to supply chain to marketing and sales. With over 80 years of experience, the Company continues to fulfill its mission to Create Value from Sorbent Minerals. To learn more about the Company, please visit oildri.com.
Media Contact
Lisa Mak
VP of Marketing, Consumer of Packaged Goods
Oil-Dri Corporation of America
Lisa.Mak@oildri.com
(312) 706-3142
This press release was published by a CLEAR® Verified individual.
The post Oil-Dri Corporation of America to Showcase Innovative Lightweight Cat Litter Products at 2025 Global Pet Expo appeared first on Crypto Insider.
]]>Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 09, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a...
The post INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris appeared first on Crypto Insider.
]]>Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options
If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, March 09, 2025 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
On February 27, 2025, Viatris issued a press release reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics. In addition, Viatris provided lower-than-expected full-year guidance for 2025. Viatris also provided an update on remediation work at a manufacturing facility in India following receipt of a warning letter and import alert from the U.S. Food and Drug Administration, advising that it was “more than halfway through its remediation efforts and expects to be completed in a few months at which time the Company anticipates requesting FDA to conduct a reinspection of the facility.”
On this news, Viatris’s stock price fell $1.71 per share, or 15.21%, to close at $9.53 per share on February 27, 2025.
To learn more about the Viatris Inc. investigation, go to www.faruqilaw.com/VTRS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1f7d2e5-d2f5-42a9-81e9-41d961ebc07d
The post INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris appeared first on Crypto Insider.
]]>Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Pacira To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 09, 2025 (GLOBE...
The post DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira appeared first on Crypto Insider.
]]>Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Pacira To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, March 09, 2025 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pacira BioSciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) and reminds investors of the March 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
According to the Complaint, on August 9, 2024, Pacira announced that the New Jersey District Court invalidated its ‘495 patent, holding that eVenus did not infringe on the ‘495 patent on the basis on obviousness and anticipation. The Complaint alleges that this ruling came shortly after Pacira’s submission of additional evidence to the Court, which the Court stated would not have any impact on the basis for the decision. The Complaint further alleges that this ruling was secondary to the same court’s ruling impacting claims construction for both Pacira’s ‘495 and ‘336 patents in eVenus’s favor.
According to the Complaint, Pacira’s announcement that its ‘495 patent was invalidated surprised investors and analysts alike as they reacted immediately to the revelations. The Complaint alleges that the price of Pacira’s common stock declined dramatically. According to the Complaint, from a closing market price of $22.36 per share on August 8, 2024, Pacira’s stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day, thereby damaging investors.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Pacira’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Pacira BioSciences, Inc. class action, go to www.faruqilaw.com/PCRX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fde2fe7b-165f-4f25-b274-82a516dcf056
The post DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira appeared first on Crypto Insider.
]]>SAN DIEGO, March 08, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Skyworks Solutions, Inc. (NASDAQ: SWKS) securities between July 30, 2024 and February 5, 2025, both dates inclusive (the “Class Period”), have until May 5, 2025 to seek appointment as lead plaintiff of the Skyworks class action lawsuit. Captioned Nunez v. Skyworks Solutions, Inc., No. 25-cv-00411 (C.D. Cal.), the Skyworks class action lawsuit charges Skyworks and certain...
The post SWKS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Skyworks Solutions, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit appeared first on Crypto Insider.
]]>SAN DIEGO, March 08, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Skyworks Solutions, Inc. (NASDAQ: SWKS) securities between July 30, 2024 and February 5, 2025, both dates inclusive (the “Class Period”), have until May 5, 2025 to seek appointment as lead plaintiff of the Skyworks class action lawsuit. Captioned Nunez v. Skyworks Solutions, Inc., No. 25-cv-00411 (C.D. Cal.), the Skyworks class action lawsuit charges Skyworks and certain of Skyworks’ top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Skyworks class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-skyworks-solutions-inc-class-action-lawsuit-swks.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
CASE ALLEGATIONS: Skyworks designs, develops, manufactures, and markets proprietary semiconductor products.
The Skyworks class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Skyworks’ projected revenue outlook and anticipated growth while also minimizing risk from smartphone upgrade cycles and macroeconomic fluctuations; (ii) Skyworks’ optimistic reports of growth, earnings potential, and anticipated margins fell short of reality as they relied far too heavily on Skyworks’ partnership with its largest customer and launch of that customer’s newest phone; and (iii) Skyworks was not equipped to execute on their perceived growth potential.
The Skyworks class action lawsuit further alleges that on February 5, 2025, Skyworks announced its financial results for the first quarter of fiscal year 2025 and provided lower-than anticipated revenue guidance for the second quarter of fiscal year 2025, attributing the results and low guidance to a “competitive landscape” that had “intensified” in recent years. On this news, the price of Skyworks stock fell more than 24%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Skyworks securities during the Class Period to seek appointment as lead plaintiff in the Skyworks class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Skyworks class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Skyworks class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Skyworks class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
info@rgrdlaw.com
The post SWKS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Skyworks Solutions, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit appeared first on Crypto Insider.
]]>